STAT+: Effort to guide treatment of cancer with novel blood tests may get boost from new research
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
BERLIN \u2014 For years, scientists have held out hope<\/a> that tests that look for the molecular fingerprints of a cancer\u2019s presence could help clinicians determine which patients need further treatment after surgery, and which can be considered truly cured after an operation. Perhaps, the thinking goes, those in the latter category could be spared from unnecessary, expensive therapies that can carry serious side effects.<\/p>\n A study<\/a> presented here Monday bolstered the case that such tests, which detect circulating tumor DNA, or ctDNA, that cancer cells slough off into the blood, could be effective tools.\u00a0<\/p>\n Researchers used the diagnostics to identify patients who appeared to have remnants of muscle-invasive bladder cancer after surgery, and directed them to treatment. Those who tested negative were allowed to live treatment-free, and were ultimately found to be at low risk of recurrence.\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n